Aclaris Therapeutics, Inc. (ACRS) Income Statement
ACRS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsACRS revenue and net income
Where ACRS's revenue goes
2025Each bar shows an amount and its share of revenue. ACRS kept −829.6% of revenue as net income.
ACRS profit margins
ACRS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −58.2% | −35.9% | +3.8% | — |
| Gross profit | −64.0% | −31.4% | +33.6% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ACRS quarterly EPS vs estimates
Aclaris Therapeutics beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.16).
ACRS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.8M | $18.7M | $31.2M | $29.8M | $6.8M | $6.5M | $4.2M | $10.1M | $1.7M | $0 |
| Cost of revenue | $2.1M | $2.8M | $18.1M | $12.0M | $4.7M | $5.1M | $4.1M | $6.8M | $1.2M | $120,000 |
| Gross profit | $5.7M | $15.9M | $13.2M | $17.8M | $2.0M | $1.3M | $172,000 | $3.2M | $476,000 | −$120,000 |
| Research & development | $52.6M | $33.6M | $98.4M | $77.8M | $43.8M | $31.7M | $64.9M | $63.0M | $39.8M | $33.5M |
| Sales, general & admin | $22.0M | $22.2M | $31.1M | $25.1M | $23.6M | $20.8M | $27.8M | $75.6M | $33.2M | $15.1M |
| Total operating expenses | $82.1M | $157.9M | $110.5M | $107.6M | $91.8M | $52.3M | $92.7M | $138.7M | $72.9M | $48.6M |
| Operating income | −$76.4M | −$141.9M | −$97.4M | −$89.9M | −$89.7M | −$50.9M | −$111.1M | −$135.4M | −$72.4M | −$48.6M |
| Interest income | $7.6M | $8.0M | — | — | — | — | — | — | — | — |
| Interest expense | — | — | — | $4.7M | $23.4M | $1.0M | $0 | $0 | $0 | $0 |
| Income before taxes | −$64.9M | −$132.1M | −$88.8M | −$86.9M | −$90.9M | −$51.3M | −$113.5M | −$132.7M | −$70.4M | −$48.1M |
| Income taxes | — | — | −$367,000 | $1.8M | $23.4M | −$182,000 | $29.3M | $2.7M | −$1.8M | −$120,000 |
| Net income | −$64.9M | −$132.1M | −$88.5M | −$86.9M | −$90.9M | −$51.2M | −$161.4M | −$132.7M | −$68.5M | −$48.1M |
| EBITDA | −$64.5M | −$51.7M | −$115.5M | −$84.4M | −$64.5M | −$49.6M | −$90.2M | −$133.5M | −$72.0M | −$48.4M |
| EPS (diluted) | −$0.53 | −$1.51 | −$1.27 | −$1.33 | −$1.63 | −$1.20 | −$3.14 | −$4.04 | −$2.47 | −$2.26 |
| Gross margin | 73.3% | 85.1% | 42.1% | 59.8% | 30.3% | 20.8% | 4.1% | 32.1% | 28.3% | — |
| Operating margin | −975.9% | −758.2% | −311.6% | −302.0% | −1,327.1% | −785.4% | −2,627.3% | −1,341.9% | −4,303.2% | — |
| Net margin | −829.6% | −705.5% | −283.1% | −292.1% | −1,344.0% | −789.2% | −3,817.2% | −1,315.4% | −4,071.5% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6M | $2.0M | $1.3M | $3.3M | $1.8M | $1.5M | $9.2M | $4.3M | $2.8M | $2.4M | $17.6M | $9.3M |
| Cost of revenue | $231,000 | $395,000 | −$803,000 | $538,000 | $1.9M | $506,000 | $9.3M | $2.4M | $1.9M | $1.8M | $6.4M | $8.2M |
| Gross profit | $1.4M | $1.6M | $2.1M | $2.8M | −$73,000 | $949,000 | −$90,000 | $1.9M | $857,000 | $558,000 | $11.1M | $1.1M |
| Research & development | $18.9M | $15.7M | $16.6M | $13.0M | $11.4M | $11.6M | $9.0M | $6.0M | $8.8M | $9.8M | $26.6M | $23.9M |
| Sales, general & admin | $6.0M | $6.7M | $5.6M | $4.9M | $5.4M | $6.1M | $5.0M | $5.7M | $4.9M | $9.3M | $8.2M | $6.8M |
| Total operating expenses | $25.6M | $23.8M | $24.8M | $19.9M | $18.3M | $19.0M | $99.6M | $12.4M | $13.7M | $19.5M | $15.2M | $32.7M |
| Operating income | −$24.2M | −$22.2M | −$22.7M | −$17.1M | −$18.4M | −$18.1M | −$99.7M | −$10.5M | −$12.9M | −$18.9M | −$4.0M | −$31.6M |
| Interest income | $1.8M | $1.5M | $1.6M | $1.8M | $2.0M | $2.2M | — | $2.0M | $1.9M | $2.0M | — | $2.3M |
| Interest expense | — | — | — | — | — | — | $4.1M | — | — | — | $1.6M | — |
| Income before taxes | −$21.5M | −$19.8M | −$19.8M | −$14.6M | −$15.4M | −$15.1M | −$96.6M | −$7.6M | −$11.0M | −$16.9M | −$1.9M | −$29.3M |
| Income taxes | — | — | — | — | — | — | — | −$7.6M | — | $199,724 | −$367,000 | −$219,000 |
| Net income | −$21.5M | −$19.8M | −$19.8M | −$14.6M | −$15.4M | −$15.1M | −$96.6M | −$7.6M | −$11.0M | −$16.9M | −$1.5M | −$29.3M |
| EBITDA | −$21.4M | −$19.7M | −$19.7M | −$14.5M | −$16.8M | −$17.7M | −$13.9M | −$9.5M | −$12.4M | −$15.9M | −$23.6M | −$29.4M |
| EPS (diluted) | −$0.15 | −$0.15 | −$0.16 | −$0.12 | −$0.13 | −$0.12 | −$1.01 | −$0.11 | −$0.15 | −$0.24 | −$0.02 | −$0.41 |
| Gross margin | 85.8% | 80.2% | 162.0% | 83.7% | −4.1% | 65.2% | −1.0% | 44.6% | 31.0% | 23.3% | 63.4% | 11.7% |
| Operating margin | −1,487.9% | −1,111.8% | −1,755.5% | −519.8% | −1,035.9% | −1,242.9% | −1,082.1% | −240.9% | −464.7% | −789.4% | −23.0% | −340.2% |
| Net margin | −1,320.1% | −993.2% | −1,528.6% | −443.0% | −868.3% | −1,036.8% | −1,048.2% | −174.6% | −397.2% | −706.5% | −8.5% | −315.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ACRS's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ACRS financial results
In fiscal year 2025 (ended December 31, 2025), Aclaris Therapeutics reported revenue of $7.8 million, down 58.2% from the year before. It had a net loss of $64.9 million, a net profit margin of −829.6%. Diluted earnings per share came to −$0.53. Over five years revenue grew at an average rate of 3.8% a year.
See the ACRS stock overview for the latest quote and news, or the ACRS chart for price history and technical indicators.
ACRS income statement FAQ
What is Aclaris Therapeutics's annual revenue?
Aclaris Therapeutics reported total revenue of $7.8 million for fiscal year 2025, which ended on December 31, 2025. That was down 58.2% from $18.7 million the previous year.
Is Aclaris Therapeutics profitable?
No. Aclaris Therapeutics reported a net loss of $64.9 million in fiscal 2025, a net profit margin of −829.6%; its operating margin was −975.9%.
What is Aclaris Therapeutics's gross margin?
Aclaris Therapeutics's gross margin was 73.3% in fiscal 2025: for every $100 of revenue, Aclaris Therapeutics kept $73 after the direct cost of its products and services.
How much does Aclaris Therapeutics spend on research and development?
Aclaris Therapeutics spent $52.6 million on research and development in fiscal 2025, 672.7% of revenue.
How fast is Aclaris Therapeutics growing?
Revenue grew 3.8% a year on average over the last five fiscal years, from $6.5 million to $7.8 million.
What are Aclaris Therapeutics's earnings per share?
Aclaris Therapeutics earned $-0.53 per diluted share in fiscal 2025, compared with $-1.51 a year earlier.
When will Aclaris Therapeutics report its next earnings?
Aclaris Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens.
When does Aclaris Therapeutics's fiscal year end?
Aclaris Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.